Literature DB >> 10645224

Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer.

R J Michalides1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10645224      PMCID： PMC500945          DOI： 10.1136/jcp.52.8.555

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


× No keyword cloud information.
  204 in total

1.  A transgenic mouse model with cyclin D1 overexpression results in cell cycle, epidermal growth factor receptor, and p53 abnormalities.

Authors:  A Mueller; R Odze; T D Jenkins; A Shahsesfaei; H Nakagawa; T Inomoto; A K Rustgi
Journal:  Cancer Res       Date:  1997-12-15       Impact factor: 12.701

2.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

3.  The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer.

Authors:  S Gazzeri; V Della Valle; L Chaussade; C Brambilla; C J Larsen; E Brambilla
Journal:  Cancer Res       Date:  1998-09-01       Impact factor: 12.701

4.  Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1.

Authors:  H Tsuda; S Hirohashi; Y Shimosato; T Hirota; S Tsugane; H Yamamoto; N Miyajima; K Toyoshima; T Yamamoto; J Yokota
Journal:  Cancer Res       Date:  1989-06-01       Impact factor: 12.701

5.  Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts.

Authors:  D E Quelle; R A Ashmun; S A Shurtleff; J Y Kato; D Bar-Sagi; M F Roussel; C J Sherr
Journal:  Genes Dev       Date:  1993-08       Impact factor: 11.361

6.  Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors.

Authors:  F Courjal; G Louason; P Speiser; D Katsaros; R Zeillinger; C Theillet
Journal:  Int J Cancer       Date:  1996-08-22       Impact factor: 7.396

7.  Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.

Authors:  R Seshadri; C S Lee; R Hui; K McCaul; D J Horsfall; R L Sutherland
Journal:  Clin Cancer Res       Date:  1996-07       Impact factor: 12.531

8.  Cyclin E, a potential prognostic marker for breast cancer.

Authors:  K Keyomarsi; N O'Leary; G Molnar; E Lees; H J Fingert; A B Pardee
Journal:  Cancer Res       Date:  1994-01-15       Impact factor: 12.701

9.  Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein.

Authors:  X Zhu; M Ohtsubo; R M Böhmer; J M Roberts; R K Assoian
Journal:  J Cell Biol       Date:  1996-04       Impact factor: 10.539

10.  E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1).

Authors:  B St Croix; C Sheehan; J W Rak; V A Flørenes; J M Slingerland; R S Kerbel
Journal:  J Cell Biol       Date:  1998-07-27       Impact factor: 10.539
View more
  21 in total

1.  Immunohistochemical expression of p16, p21, p27 and cyclin D1 in oral nevi and melanoma.

Authors:  Bruno Augusto Benevenuto de Andrade; Jorge Esquiche León; Román Carlos; Wilson Delgado-Azañero; Adalberto Mosqueda-Taylor; Oslei Paes de Almeida
Journal:  Head Neck Pathol       Date:  2012-02-05

Review 2.  Cell cycle control as a basis for cancer chemoprevention through dietary agents.

Authors:  Syed Musthapa Meeran; Santosh Kumar Katiyar
Journal:  Front Biosci       Date:  2008-01-01

3.  p21(waf) correlates with DNA replication but not with prognosis in invasive breast cancer.

Authors:  U J Göhring; A Bersch; M Becker; W Neuhaus; T Schöndorf
Journal:  J Clin Pathol       Date:  2001-11       Impact factor: 3.411

4.  Inhibition of cell growth and induction of apoptosis in ovarian carcinoma cell lines CaOV3 and SKOV3 by natural withanolide Withaferin A.

Authors:  Xuan Zhang; Abbas K Samadi; Katherine F Roby; Barbara Timmermann; Mark S Cohen
Journal:  Gynecol Oncol       Date:  2011-12-03       Impact factor: 5.482

5.  The prognostic implication of the expression of EGFR, p53, cyclin D1, Bcl-2 and p16 in primary locally advanced oral squamous cell carcinoma cases: a tissue microarray study.

Authors:  Monica Charlotte Solomon; M S Vidyasagar; Donald Fernandes; Vasudev Guddattu; Mary Mathew; Ankur Kaur Shergill; Sunitha Carnelio; Chetana Chandrashekar
Journal:  Med Oncol       Date:  2016-11-05       Impact factor: 3.064

6.  Chemoprevention of Breast Cancer by Transdermal Delivery of α-Santalol through Breast Skin and Mammary Papilla (Nipple).

Authors:  Kaushalkumar Dave; Fahd M Alsharif; Saiful Islam; Chandradhar Dwivedi; Omathanu Perumal
Journal:  Pharm Res       Date:  2017-06-06       Impact factor: 4.200

7.  Correlation of cell cycle regulatory proteins (p53 and p16(ink)⁴(a)) and bcl-2 oncoprotein with mitotic index and thickness of primary cutaneous malignant melanoma.

Authors:  Miloš Kostov; Zaklina Mijović; Dragan Mihailović; Snežana Cerović; Miroslav Stojanović; Marija Jelić
Journal:  Bosn J Basic Med Sci       Date:  2010-11       Impact factor: 3.363

Review 8.  Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective.

Authors:  Judith M de Bont; Roger J Packer; Erna M Michiels; Monique L den Boer; Rob Pieters
Journal:  Neuro Oncol       Date:  2008-08-01       Impact factor: 12.300

9.  Comparison of the inhibitory effects of three transcriptional variants of CDKN2A in human lung cancer cell line A549.

Authors:  Wei Zhang; Jing Zhu; Jing Bai; Hui Jiang; Fangli Liu; An Liu; Peng Liu; Guohua Ji; Rongwei Guan; Donglin Sun; Wei Ji; Yang Yu; Yan Jin; Xiangning Meng; Songbin Fu
Journal:  J Exp Clin Cancer Res       Date:  2010-06-17

10.  p16INK4A alterations are accompanied by aberrant protein immunostaining in endometrial carcinomas.

Authors:  Andrzej Semczuk; Carsten Boltze; Barbara Marzec; Anna Szczygielska; Albert Roessner; Regine Schneider-Stock
Journal:  J Cancer Res Clin Oncol       Date:  2003-08-14       Impact factor: 4.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.